Adicet Bio is dedicated to pioneering advanced immune cell therapies, leveraging state-of-the-art technologies to harness the power of gamma delta T cells. These cells are engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enhance selective tumor targeting and stimulate both innate and adaptive anti-tumor immune responses. The company's research and development efforts focus on improving the persistence and efficacy of these therapies, aiming for durable activity in patients with various cancers and autoimmune diseases. This segment includes preclinical studies, clinical trials, and strategic collaborations to expand the application of gamma delta T cell therapies across different therapeutic areas. The ultimate goal is to provide innovative treatments that significantly improve patient outcomes and quality of life.

This segment focuses on the development of allogeneic gamma delta T cell therapies for autoimmune diseases, leveraging the unique properties of these cells to modulate the immune system and address the underlying causes of autoimmune disorders. Adicet Bio is currently conducting a Phase 1 clinical trial of ADI-001 in autoimmune diseases, including Systemic Sclerosis (SSc). The company's research and development activities include preclinical studies to identify and validate new targets, as well as clinical trials to evaluate the safety and efficacy of its therapies in patients with autoimmune diseases. The goal is to develop innovative treatments that can provide long-term remission and improve the quality of life for patients with these debilitating conditions. This segment also involves strategic partnerships and collaborations to expand the application of gamma delta T cell therapies in autoimmune diseases.